<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39358543</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1740-634X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</Title><ISOAbbreviation>Neuropsychopharmacology</ISOAbbreviation></Journal><ArticleTitle>A digital intervention for cognitive deficits following COVID-19: a randomized clinical trial.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41386-024-01995-z</ELocationID><Abstract><AbstractText>Post-COVID-19 cognitive deficits are common, persistent, and disabling. Evidence on effective treatments is limited. The goal of this study was to investigate the efficacy of a digital intervention to reduce cognitive and functional deficits in adults with persistent post-COVID-19 cognitive dysfunction. We used the remotely-delivered intervention in a randomized clinical trial conducted from July 13, 2021 to April 26, 2023. We hypothesized that participants in the intervention group would improve in measures of cognition and daily functioning. Participants were adults with cognitive deficits persisting &gt;4 weeks following acute COVID-19 illness. Of 183 participants screened, 110 were enrolled; 98 participants (78.6% female; mean age&#x2009;=&#x2009;48.1) completed at least one study visit. Participants were randomized 1:1 to the intervention (AKL-T01) or waitlist control. AKL-T01 is a digital therapeutic using a videogame interface to target attention and executive control. The intervention was delivered remotely for 6 weeks. The primary outcome was change in performance on a sustained attention measure (Digit Symbol Matching Task). The difference in the primary outcome between the intervention (n&#x2009;=&#x2009;49) and controls (n&#x2009;=&#x2009;49) was not statistically significant (F [3,261]&#x2009;=&#x2009;0.12, p&#x2009;=&#x2009;0.95). Secondary cognitive outcomes of task-switching (F[3,262]&#x2009;=&#x2009;2.78, p&#x2009;=&#x2009;0.04) and processing speed (F[3,267]&#x2009;=&#x2009;4.57, p&#x2009;=&#x2009;0.004) improved in the intervention relative to control. Secondary measures of functioning also improved in the intervention relative to control, including disability (F[1,82]&#x2009;=&#x2009;4.02, p&#x2009;=&#x2009;0.05) and quality of life (F[3,271]&#x2009;=&#x2009;2.66, p&#x2009;=&#x2009;0.05). Exploratory analyses showed a greater reduction in total fatigue (F[1,85]&#x2009;=&#x2009;4.51, p&#x2009;=&#x2009;0.04), cognitive fatigue (F[1,85]&#x2009;=&#x2009;7.20, p&#x2009;=&#x2009;0.009), and anxiety (F[1,87]&#x2009;=&#x2009;7.42, p&#x2009;=&#x2009;0.008) in the intervention relative to control. Despite the lack of improvement in sustained attention, select post-COVID-19 cognitive deficits may be ameliorated by targeted cognitive training with AKL-T01, with associated improvements in quality of life and fatigue. If replicated, the scalable nature of this digital intervention may help address substantial need for accessible, effective treatments among individuals with long COVID.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Victoria</LastName><ForeName>Lindsay W</ForeName><Initials>LW</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Oberlin</LastName><ForeName>Lauren E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, AdventHealth Research Institute, Orlando, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ilieva</LastName><ForeName>Irena P</ForeName><Initials>IP</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaywant</LastName><ForeName>Abhishek</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4307-5742</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rehabilitation Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanellopoulos</LastName><ForeName>Dora</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercaldi</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Akili Interactive Labs, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stamatis</LastName><ForeName>Caitlin A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Akili Interactive Labs, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farlow</LastName><ForeName>Deborah N</ForeName><Initials>DN</Initials><AffiliationInfo><Affiliation>Akili Interactive Labs, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kollins</LastName><ForeName>Scott H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Akili Interactive Labs, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tisor</LastName><ForeName>Ochuwa</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Sama</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doreste-Mendez</LastName><ForeName>Raura</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perlis</LastName><ForeName>Roy H</ForeName><Initials>RH</Initials><Identifier Source="ORCID">0000-0002-5862-6757</Identifier><AffiliationInfo><Affiliation>Center for Quantitative Health and Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gunning</LastName><ForeName>Faith M</ForeName><Initials>FM</Initials><Identifier Source="ORCID">0000-0003-1854-9969</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Weill Cornell Medicine, New York, NY, USA. fgd2002@med.cornell.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, NY, USA. fgd2002@med.cornell.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuropsychopharmacology</MedlineTA><NlmUniqueID>8904907</NlmUniqueID><ISSNLinking>0893-133X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>23</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39358543</ArticleId><ArticleId IdType="doi">10.1038/s41386-024-01995-z</ArticleId><ArticleId IdType="pii">10.1038/s41386-024-01995-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO. Update to Requirements for Reporting COVID-19 Surveillance Data under the International Health Regulations (IHR 2005): Addendum to Public Health Surveillance for COVID-19 Interim Guidance, 25 August 2023. Geneva, Switzerland: World Health Organization; 2023.</Citation></Reference><Reference><Citation>Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18:e1003773.</Citation><ArticleIdList><ArticleId IdType="pubmed">34582441</ArticleId><ArticleId IdType="pmc">8478214</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis RH, Santillana M, Ognyanova K, Safarpour A, Lunz Trujillo K, Simonson MD, et al. Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw open. 2022;5:e2238804&#x2013;e2238804.</Citation><ArticleIdList><ArticleId IdType="pubmed">36301542</ArticleId><ArticleId IdType="pmc">9614581</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.38804</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaywant A, Gunning FM, Oberlin LE, Santillana M, Ognyanova K, Druckman JN, et al. Cognitive Symptoms of Post&#x2013;COVID-19 Condition and Daily Functioning. JAMA Netw Open. 2024;7:e2356098&#x2013;e2356098.</Citation><ArticleIdList><ArticleId IdType="pubmed">38353947</ArticleId><ArticleId IdType="pmc">10867690</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.56098</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM, et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav Immun. 2022;101:93&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">34973396</ArticleId><ArticleId IdType="doi">10.1016/j.bbi.2021.12.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheetham NJ, Penfold R, Giunchiglia V, Bowyer V, Sudre CH, Canas LS, et al. The effects of COVID-19 on cognitive performance in a community-based cohort: a COVID symptom study biobank prospective cohort study. EClinicalMedicine. 2023;62:102086.</Citation><ArticleIdList><ArticleId IdType="pubmed">37654669</ArticleId><ArticleId IdType="pmc">10466229</ArticleId><ArticleId IdType="doi">10.1016/j.eclinm.2023.102086</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter RS, Nieters A, Kr&#xe4;usslich H-G, Brockmann SO, G&#xf6;pel S, Kindle G, et al. Post-acute sequelae of covid-19 six to 12 months after infection: population based study. bmj. 2022;379:e071050.</Citation><ArticleIdList><ArticleId IdType="pubmed">36229057</ArticleId><ArticleId IdType="doi">10.1136/bmj-2022-071050</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampshire A, Azor A, Atchison C, Trender W, Hellyer PJ, Giunchiglia V, et al. Cognition and Memory after Covid-19 in a Large Community Sample. N Engl J Med. 2024;390:806&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">38416429</ArticleId><ArticleId IdType="pmc">7615803</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2311330</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng N, Zhao Y-M, Yan W, Li C, Lu QD, Liu L, et al. A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic: call for research priority and action. Mol Psychiatry. 2023;28:423&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">35668159</ArticleId><ArticleId IdType="doi">10.1038/s41380-022-01614-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall PA, Meng G, Hudson A, Sakib MN, Hitchman SC, MacKillop J, et al. Cognitive function following SARS-CoV-2 infection in a population-representative Canadian sample. Brain Behav Immun Health. 2022;21:100454.</Citation><ArticleIdList><ArticleId IdType="pubmed">35340304</ArticleId><ArticleId IdType="pmc">8934755</ArticleId><ArticleId IdType="doi">10.1016/j.bbih.2022.100454</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertuccelli M, Ciringione L, Rubega M, Bisiacchi P, Masiero S, Del Felice A. Cognitive impairment in people with previous COVID-19 infection: A scoping review. Cortex. 2022;154:212&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">35780756</ArticleId><ArticleId IdType="pmc">9187867</ArticleId><ArticleId IdType="doi">10.1016/j.cortex.2022.06.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamontagne SJ, Winters MF, Pizzagalli DA, Olmstead MC. Post-acute sequelae of COVID-19: Evidence of mood &amp; cognitive impairment. Brain Behav Immun Health. 2021;17:100347.</Citation><ArticleIdList><ArticleId IdType="pubmed">34549199</ArticleId><ArticleId IdType="pmc">8437695</ArticleId><ArticleId IdType="doi">10.1016/j.bbih.2021.100347</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaywant A, Vanderlind WM, Alexopoulos GS, Fridman CB, Perlis RH, Gunning FM. Frequency and profile of objective cognitive deficits in hospitalized patients recovering from COVID-19. Neuropsychopharmacology. 2021;46:2235&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">33589778</ArticleId><ArticleId IdType="pmc">7884062</ArticleId><ArticleId IdType="doi">10.1038/s41386-021-00978-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik P, Patel K, Pinto C, Jaiswal R, Tirupathi R, Pillai S, et al. Post&#x2010;acute COVID&#x2010;19 syndrome (PCS) and health&#x2010;related quality of life (HRQoL)&#x2014;A systematic review and meta&#x2010;analysis. J Med Virol. 2022;94:253&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">34463956</ArticleId><ArticleId IdType="doi">10.1002/jmv.27309</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabacof L, Tosto-Mancuso J, Wood J, Cortes M, Kontorovich A, McCarthy D, et al. Post-acute COVID-19 syndrome negatively impacts physical function, cognitive function, health-related quality of life, and participation. Am J Phys Med Rehabil. 2022;101:48&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">34686631</ArticleId><ArticleId IdType="doi">10.1097/PHM.0000000000001910</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan M, Wang X, Gong M, Wang Q, Li Y, Jia J. Post-COVID cognitive dysfunction: current status and research recommendations for high risk population. Lancet Reg Heal Pacific. 2023;38:100836.</Citation></Reference><Reference><Citation>Fesharaki Zadeh A, Arnsten AFT, Wang M. Scientific Rationale for the Treatment of Cognitive Deficits from Long COVID. Neurol Int. 2023;15:725&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">37368329</ArticleId><ArticleId IdType="pmc">10303664</ArticleId><ArticleId IdType="doi">10.3390/neurolint15020045</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf6;ller M, Borg K, Janson C, Lerm M, Normark J, Niward K. Cognitive dysfunction in post&#x2010;COVID&#x2010;19 condition: Mechanisms, management, and rehabilitation. J Intern Med. 2023;294:563&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">37766515</ArticleId><ArticleId IdType="doi">10.1111/joim.13720</ArticleId></ArticleIdList></Reference><Reference><Citation>Victor MM, M&#xfc;ller Haas L, Grevet EH, Rohde LA. Successful Treatment of Post-COVID-19 ADHD-like Syndrome: A Case Report. J Atten Disord. 2023;27:1092&#x2013;98.</Citation></Reference><Reference><Citation>Manu P. Repurposing Drugs for Post&#x2013;COVID-19 Fatigue Syndrome: Methylphenidate, Duloxetine, and Brexpiprazole. Am J Ther. 2022;29:e229&#x2013;e230.</Citation><ArticleIdList><ArticleId IdType="pubmed">35389574</ArticleId><ArticleId IdType="doi">10.1097/MJT.0000000000001471</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacks-Zimmerman A, Bergquist TF, Farr EM, Cornwell MA, Kanellopoulos D. Rehabilitation of Neuropsychiatric Symptoms in Patients With Long COVID: Position Statement. Arch Phys Med Rehabil. 2023;104:350&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">36272444</ArticleId><ArticleId IdType="doi">10.1016/j.apmr.2022.10.001</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ham IJM, van der Vaart R, Miedema A, Visser-Meily JMA, van der Kuil MNA. Healthcare professionals&#x2019; acceptance of digital cognitive rehabilitation. Front Psychol. 2020;11:617886.</Citation><ArticleIdList><ArticleId IdType="pubmed">33324309</ArticleId><ArticleId IdType="pmc">7725711</ArticleId><ArticleId IdType="doi">10.3389/fpsyg.2020.617886</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiaravalloti ND, Alexander A. Crossing the synapse: Strengthening the connection between clinical research and clinical practice of cognitive rehabilitation. Front Rehabil Sci. 2023;4:1084071.</Citation></Reference><Reference><Citation>Kollins SH, DeLoss DJ, Ca&#xf1;adas E, Lutz J, Findling RL, Keefe R, et al. A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial. Lancet Digit Heal. 2020;2:e168&#x2013;e178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(20)30017-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Keefe RSE, Ca&#xf1;adas E, Farlow D, Etkin A. Digital intervention for cognitive deficits in major depression: a randomized controlled trial to assess efficacy and safety in adults. Am J Psychiatry. 2022;179:482&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">35410496</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.21020125</ArticleId></ArticleIdList></Reference><Reference><Citation>Bove R, Rowles W, Zhao C, Anderson A, Friedman S, Langdon D, et al. A novel in-home digital treatment to improve processing speed in people with multiple sclerosis: a pilot study. Mult Scler J. 2021;27:778&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458520930371</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis NO, Bower J, Kollins SH. Proof-of-concept study of an at-home, engaging, digital intervention for pediatric ADHD. PLoS One. 2018;13:e0189749.</Citation><ArticleIdList><ArticleId IdType="pubmed">29324745</ArticleId><ArticleId IdType="pmc">5764249</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0189749</ArticleId></ArticleIdList></Reference><Reference><Citation>Anguera JA, Brandes-Aitken AN, Antovich AD, Rolle CE, Desai SS, Marco EJ. A pilot study to determine the feasibility of enhancing cognitive abilities in children with sensory processing dysfunction. PLoS One. 2017;12:e0172616.</Citation><ArticleIdList><ArticleId IdType="pubmed">28380008</ArticleId><ArticleId IdType="pmc">5381761</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0172616</ArticleId></ArticleIdList></Reference><Reference><Citation>Anguera JA, Gunning FM, Are&#xe1;n PA. Improving late life depression and cognitive control through the use of therapeutic video game technology: A proof-of-concept randomized trial. Depress Anxiety. 2017;34:508&#x2013;17. https://doi.org/10.1002/da.22588</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/da.22588</ArticleId><ArticleId IdType="pubmed">28052513</ArticleId><ArticleId IdType="pmc">6093618</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunning FM, Anguera JA, Victoria LW, Are&#xe1;n PA. A digital intervention targeting cognitive control network dysfunction in middle age and older adults with major depression. Transl Psychiatry. 2021;11. https://doi.org/10.1038/s41398-021-01386-8</Citation></Reference><Reference><Citation>Kollins SH, Childress A, Heusser AC, Lutz J. Effectiveness of a digital therapeutic as adjunct to treatment with medication in pediatric ADHD. NPJ Digit Med. 2021;4:58.</Citation><ArticleIdList><ArticleId IdType="pubmed">33772095</ArticleId><ArticleId IdType="pmc">7997870</ArticleId><ArticleId IdType="doi">10.1038/s41746-021-00429-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamatis CA, Mercaldi C, Kollins SH. A Single-Arm Pivotal Trial to Assess the Efficacy of Akl-T01, a Novel Digital Intervention for Attention, in Adults Diagnosed With ADHD. J Am Acad Child Adolesc Psychiatry. 2023;62:S318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaac.2023.09.510</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroop J. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18:643&#x2013;62. https://doi.org/10.1037/h0054651</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/h0054651</ArticleId></ArticleIdList></Reference><Reference><Citation>Golden C, Freshwater SM, Golden Z. Stroop color and word test: A manual for clinical and experimental uses. Chicago, Illinois: Stoelting Company. 1978;1&#x2013;32.</Citation></Reference><Reference><Citation>Ricker JH, Axelrod BN, Houtler BD. Clinical validation of the oral trail making test. Cogn Behav Neurol. 1996;9:50&#x2013;53.</Citation></Reference><Reference><Citation>Mrazik M, Millis S, Drane DL. The oral trail making test: effects of age and concurrent validity. Arch Clin Neuropsychol. 2010;25:236&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">20197294</ArticleId><ArticleId IdType="pmc">2858599</ArticleId><ArticleId IdType="doi">10.1093/arclin/acq006</ArticleId></ArticleIdList></Reference><Reference><Citation>Grace J, Malloy PF. Frontal systems behavior scale: Professional manual. Lutz, Florida: Psychological Assessment Resources. 2001.</Citation></Reference><Reference><Citation>Leong V, Raheel K, Sim JY, Kacker K, Karlaftis VM, Vassiliu C, et al. A new remote guided method for supervised web-based cognitive testing to ensure high-quality data: development and usability study. J Med Internet Res. 2022;24:e28368.</Citation><ArticleIdList><ArticleId IdType="pubmed">34989691</ArticleId><ArticleId IdType="pmc">8778570</ArticleId><ArticleId IdType="doi">10.2196/28368</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown T, Zakzanis KK. A review of the reliability of remote neuropsychological assessment. Appl Neuropsychol Adult. 2023 Nov 24:1&#x2013;7. Epub ahead of print.</Citation></Reference><Reference><Citation>Germine L, Nakayama K, Duchaine BC, Chabris CF, Chatterjee G, Wilmer JB. Is the Web as good as the lab? Comparable performance from Web and lab in cognitive/perceptual experiments. Psychon Bull Rev. 2012;19:847&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">22829343</ArticleId><ArticleId IdType="doi">10.3758/s13423-012-0296-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Germine L, Reinecke K, Chaytor NS. Digital neuropsychology: Challenges and opportunities at the intersection of science and software. Clin Neuropsychol. 2019;33:271&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">30614374</ArticleId><ArticleId IdType="doi">10.1080/13854046.2018.1535662</ArticleId></ArticleIdList></Reference><Reference><Citation>Passell E, Dillon DG, Baker JT, Vogel SC, Scheuer LS, Mirin N, et al. Digital cognitive assessment: results from the TestMyBrain NIMH Research Domain Criteria (RDoC) field test battery report. Published online 2019.</Citation></Reference><Reference><Citation>Chaytor NS, Barbosa-Leiker C, Germine LT, Fonseca LM, McPherson SM, Tuttle KR. Construct validity, ecological validity and acceptance of self-administered online neuropsychological assessment in adults. Clin Neuropsychol. 2021;35:148&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">32883156</ArticleId><ArticleId IdType="doi">10.1080/13854046.2020.1811893</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartshorne JK, Germine LT. When does cognitive functioning peak? The asynchronous rise and fall of different cognitive abilities across the life span. Psychol Sci. 2015;26:433&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">25770099</ArticleId><ArticleId IdType="doi">10.1177/0956797614567339</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Strong RW, Jung L, Li FH, Grinspoon L, Scheuer LS, et al. The TestMyBrain digital neuropsychology toolkit: Development and psychometric characteristics. J Clin Exp Neuropsychol. 2021;43:786&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">34907842</ArticleId><ArticleId IdType="pmc">8922997</ArticleId><ArticleId IdType="doi">10.1080/13803395.2021.2002269</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith A. Symbol Digit Modalities Test. Los Angeles: Western psychological services; 1973.</Citation></Reference><Reference><Citation>Sheridan LK, Fitzgerald HE, Adams KM, Nigg JT, Martel MM, Puttler LI, et al. Normative Symbol Digit Modalities Test performance in a community-based sample. Arch Clin Neuropsychol. 2006;21:23&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">16139470</ArticleId><ArticleId IdType="doi">10.1016/j.acn.2005.07.003</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xdc;st&#xfc;n TB. Measuring Health and Disability: Manual for WHO Disability Assessment Schedule WHODAS 2.0. Geneva, Switzerland: World Health Organization; 2010.</Citation></Reference><Reference><Citation>Cella D, Lai J-S, Nowinski CJ, Victorson D, Peterman A, Miller D, et al. Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology. Neurology. 2012;78:1860&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">22573626</ArticleId><ArticleId IdType="pmc">3369516</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e318258f744</ArticleId></ArticleIdList></Reference><Reference><Citation>Gershon RC, Lai JS, Bode R, Choi S, Moy C, Bleck T, et al. Neuro-QOL: quality of life item banks for adults with neurological disorders: item development and calibrations based upon clinical and general population testing. Qual Life Res. 2012;21:475&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">21874314</ArticleId><ArticleId IdType="doi">10.1007/s11136-011-9958-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci. 1994;21:9&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">8180914</ArticleId><ArticleId IdType="doi">10.1017/S0317167100048691</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson RD. Psychometric properties of the modified fatigue impact scale. Int J MS Care. 2013;15:15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">24453758</ArticleId><ArticleId IdType="pmc">3883028</ArticleId><ArticleId IdType="doi">10.7224/1537-2073.2012-019</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer RL, Kroenke K, Williams JBW, L&#xf6;we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16717171</ArticleId><ArticleId IdType="doi">10.1001/archinte.166.10.1092</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke K, Spitzer RL, Williams JBW. The PHQ&#x2010;9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">11556941</ArticleId><ArticleId IdType="pmc">1495268</ArticleId><ArticleId IdType="doi">10.1046/j.1525-1497.2001.016009606.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakens D. Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs. Front Psychol. 2013;4:62627.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2013.00863</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J. Statistical Power Analysis for the Behavioral Sciences. Oxfordshire, UK: Routledge; 2013.</Citation></Reference><Reference><Citation>Berger A, Kiefer M. Comparison of different response time outlier exclusion methods: A simulation study. Front Psychol. 2021;12:675558.</Citation><ArticleIdList><ArticleId IdType="pubmed">34194371</ArticleId><ArticleId IdType="pmc">8238084</ArticleId><ArticleId IdType="doi">10.3389/fpsyg.2021.675558</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch JJ, Eifert GH, Davies C, Vilardaga JCP, Rose RD, Craske MG. Randomized clinical trial of cognitive behavioral therapy (CBT) versus acceptance and commitment therapy (ACT) for mixed anxiety disorders. J Consult Clin Psychol. 2012;80:750&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">22563639</ArticleId><ArticleId IdType="pmc">4718567</ArticleId><ArticleId IdType="doi">10.1037/a0028310</ArticleId></ArticleIdList></Reference><Reference><Citation>Quigley L, Wen A, Dobson KS. Cognitive control over emotional information in current and remitted depression. Behav Res Ther. 2020;132:103658.</Citation><ArticleIdList><ArticleId IdType="pubmed">32615318</ArticleId><ArticleId IdType="doi">10.1016/j.brat.2020.103658</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg. 2014;12:1495&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2014.07.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker S, Goodfellow H, Pookarnjanamorakot P, Murray E, Bindman J, Blandford A, et al. Impact of fatigue as the primary determinant of functional limitations among patients with post-COVID-19 syndrome: a cross-sectional observational study. BMJ Open. 2023;13:e069217.</Citation><ArticleIdList><ArticleId IdType="pubmed">37286327</ArticleId><ArticleId IdType="pmc">10335413</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2022-069217</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, Wei, H, Low, RJ, Re'em, Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019.</Citation></Reference><Reference><Citation>Von Ah D, Carpenter JS, Saykin A, Monahan P, Wu J, Yu M, et al. Advanced cognitive training for breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat. 2012;135:799&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10549-012-2210-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray VJ, Dhillon HM, Bell ML, Kabourakis, M, Fiero, MH, Yip, D, et al. Evaluation of a web-based cognitive rehabilitation program in cancer survivors reporting cognitive symptoms after chemotherapy. Am Soc Clin Oncol. 2017;35:217&#x2013;225.</Citation></Reference><Reference><Citation>Rosti-Otaj&#xe4;rvi E, M&#xe4;ntynen A, Koivisto K, Huhtala H, H&#xe4;m&#xe4;l&#xe4;inen P. Patient-related factors may affect the outcome of neuropsychological rehabilitation in multiple sclerosis. J Neurol Sci. 2013;334:106&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">23968849</ArticleId><ArticleId IdType="doi">10.1016/j.jns.2013.07.2520</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">36639608</ArticleId><ArticleId IdType="pmc">9839201</ArticleId><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Saltzman LY, Longo M, Hansel TC. Long-COVID stress symptoms: Mental health, anxiety, depression, or posttraumatic stress. Psychol Trauma Theory, Res Pract Policy. 2023. Epub ahead of print.</Citation></Reference><Reference><Citation>Johnson SU, Amundsen OM, Johnson MS, Hoffart A, Hals&#xf8;y &#xd8;, Skjerdingstad N, et al. Psychiatric symptoms in COVID-19-positive individuals in the general population: Trajectories of depression, anxiety, and insomnia. Psychiatry Res. 2022;317:114806.</Citation><ArticleIdList><ArticleId IdType="pubmed">36084543</ArticleId><ArticleId IdType="pmc">9392896</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2022.114806</ArticleId></ArticleIdList></Reference><Reference><Citation>Park N, Oberlin L, Cherestal S, Bueno Castellano C, Dargis M, Wyka KE, et al. Trajectory and outcomes of psychiatric symptoms in first-wave COVID-19 survivors referred for telepsychotherapy. Gen Hosp Psychiatry. 2023;81:86&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">36801082</ArticleId><ArticleId IdType="pmc">9896849</ArticleId><ArticleId IdType="doi">10.1016/j.genhosppsych.2023.01.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaywant A, Vanderlind WM, Boas SJ, Dickerman AL. Behavioral interventions in acute COVID-19 recovery: A new opportunity for integrated care. Gen Hosp Psychiatry. 2021;69:113&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">32654787</ArticleId><ArticleId IdType="doi">10.1016/j.genhosppsych.2020.07.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Li R, Wu Z, Yang X, Zhao M, Liu J, et al. Therapeutic strategies for critically ill patients with COVID-19. Ann Intensive Care. 2020;10:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-020-00661-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Li X, Jiang J, Xu X, Wu J, Xu Y, et al. The effect of cognitive behavioral therapy on depression, anxiety, and stress in patients with COVID-19: a randomized controlled trial. Front Psychiatry. 2020;11:580827.</Citation><ArticleIdList><ArticleId IdType="pubmed">33192723</ArticleId><ArticleId IdType="pmc">7661854</ArticleId><ArticleId IdType="doi">10.3389/fpsyt.2020.580827</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Qiao D, Xu Y, Zhao W, Yang Y, Wen D, et al. The efficacy of computerized cognitive behavioral therapy for depressive and anxiety symptoms in patients with COVID-19: randomized controlled trial. J Med Internet Res. 2021;23:e26883.</Citation><ArticleIdList><ArticleId IdType="pubmed">33900931</ArticleId><ArticleId IdType="pmc">8128049</ArticleId><ArticleId IdType="doi">10.2196/26883</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinn R, Gao L, Schoeneich S, Dahmen A, Anand Kumar V, Becker P, et al. Digital Interventions for Treating Post-COVID or Long-COVID Symptoms: Scoping Review. J Med Internet Res. 2023;25:e45711.</Citation><ArticleIdList><ArticleId IdType="pubmed">36943909</ArticleId><ArticleId IdType="pmc">10131666</ArticleId><ArticleId IdType="doi">10.2196/45711</ArticleId></ArticleIdList></Reference><Reference><Citation>Skilbeck L. Patient-led integrated cognitive behavioural therapy for management of long COVID with comorbid depression and anxiety in primary care-a case study. Chronic Illn. 2022;18:691&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">35821571</ArticleId><ArticleId IdType="doi">10.1177/17423953221113605</ArticleId></ArticleIdList></Reference><Reference><Citation>Huth D, Br&#xe4;scher A-K, Tholl S, Fiess, J, Birke, G, Herrmann, C, et al. Cognitive-behavioral therapy for patients with post-COVID-19 condition (CBT-PCC): a feasibility trial. Psychol Med. 2024;54:1122&#x2013;32.</Citation></Reference><Reference><Citation>Mazza MG, Palladini M, Poletti S, Benedetti F. Post-COVID-19 depressive symptoms: epidemiology, pathophysiology, and pharmacological treatment. CNS Drugs. 2022;36:681&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">35727534</ArticleId><ArticleId IdType="pmc">9210800</ArticleId><ArticleId IdType="doi">10.1007/s40263-022-00931-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Noda Y, Sato A, Shichi M, Sato A, Fujii K, Iwasa M, et al. Real world research on transcranial magnetic stimulation treatment strategies for neuropsychiatric symptoms with long-COVID in Japan. Asian J Psychiatr. 2023;81:103438.</Citation><ArticleIdList><ArticleId IdType="pubmed">36610206</ArticleId><ArticleId IdType="doi">10.1016/j.ajp.2022.103438</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Molina A, Garc&#xed;a-Carmona S, Espi&#xf1;a-Bou M, Rodr&#xed;guez-Rajo P, S&#xe1;nchez-Carri&#xf3;n R, Ense&#xf1;at-Cantallops A. Neuropsychological rehabilitation for post&#x2013;COVID-19 syndrome: results of a clinical programme and six-month follow up. Neurologia. 2022;39:592&#x2013;603.</Citation></Reference><Reference><Citation>Palladini M, Bravi B, Colombo F, Caselani E, Di Pasquasio C, D'Orsi G, et al. Cognitive remediation therapy for post-acute persistent cognitive deficits in COVID-19 survivors: a proof-of-concept study. Neuropsychol Rehabil. 2023;33:1207&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">35583357</ArticleId><ArticleId IdType="doi">10.1080/09602011.2022.2075016</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasting AS, Herzig S, Obrig H, Schroeter ML, Villringer A, Th&#xf6;ne-Otto AIT. The Leipzig Treatment Program for Interdisciplinary Diagnosis and Therapy of Neurocognitive Post-COVID Symptoms. Zeitschrift f&#xfc;r Neuropsychol. 2023;32:71&#x2013;83.</Citation></Reference><Reference><Citation>Jacobs MM, Evans E, Ellis C. Racial, ethnic, and sex disparities in the incidence and cognitive symptomology of long COVID-19. J Natl Med Assoc. 2023;115:233&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">36792456</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammadi S, Ghaderi S. Post-COVID-19 conditions: a systematic review on advanced magnetic resonance neuroimaging findings. Neurol Sci. 2024;45:1815&#x2013;33.</Citation></Reference><Reference><Citation>Manganotti P, Michelutti M, Furlanis G, Deodato M, Stella AB. Deficient GABABergic and glutamatergic excitability in the motor cortex of patients with long-COVID and cognitive impairment. Clin Neurophysiol. 2023;151:83&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">37210757</ArticleId><ArticleId IdType="pmc">10170904</ArticleId><ArticleId IdType="doi">10.1016/j.clinph.2023.04.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Marinkovic K, White DR, Alderson Myers A, Parker KS, Arienzo D, Mason GF. Cortical GABA Levels Are Reduced in Post-Acute COVID-19 Syndrome. Brain Sci. 2023;13:1666.</Citation><ArticleIdList><ArticleId IdType="pubmed">38137114</ArticleId><ArticleId IdType="pmc">10741691</ArticleId><ArticleId IdType="doi">10.3390/brainsci13121666</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604:697&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">35255491</ArticleId><ArticleId IdType="pmc">9046077</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-04569-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp JA, Reisert M, Dressing A, G&#xf6;tz V, Kellner E, Mast H, et al. Cerebral microstructural alterations in Post-COVID-condition are related to cognitive impairment, olfactory dysfunction and fatigue. Nat Commun. 2024;15:4256.</Citation><ArticleIdList><ArticleId IdType="pubmed">38762609</ArticleId><ArticleId IdType="pmc">11102465</ArticleId><ArticleId IdType="doi">10.1038/s41467-024-48651-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Scardua-Silva L, Amorim da Costa B, Karmann Aventurato &#xcd;, Batista Joao R, Machado de Campos B, Rabelo de Brito M, et al. Microstructural brain abnormalities, fatigue, and cognitive dysfunction after mild COVID-19. Sci Rep. 2024;14:1758.</Citation><ArticleIdList><ArticleId IdType="pubmed">38242927</ArticleId><ArticleId IdType="pmc">10798999</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-52005-7</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>